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Toll-like receptors mediate important cellular immune responses upon activation via various pathogenic stimuli such as bacterial
or viral components. The activation and subsequent secretion of cytokines and proinflammatory factors occurs in the whole body
including the brain. The subsequent inflammatory response is crucial for the immune system to clear the pathogen(s) from the
body via the innate and adaptive immune response. Within the brain, astrocytes, neurons, microglia, and oligodendrocytes all
bear unique compositions of Toll-like receptors. Besides pathogens, cellular damage and abnormally folded protein aggregates,
such as tau and Amyloid beta peptides, have been shown to activate Toll-like receptors in neurodegenerative diseases such as
Alzheimer’s disease.This review provides an overview of the different cell type-specific Toll-like receptors of the human brain, their
activation mode, and subsequent cellular response, as well as their activation in Alzheimer’s disease. Finally, we critically evaluate
the therapeutic potential of targeting Toll-like receptors for treatment of Alzheimer’s disease as well as discussing the limitation of
mouse models in understanding Toll-like receptor function in general and in Alzheimer’s disease.
1. Introduction
For many years it was believed that the brain did not possess
an immune system, due to its isolation via the blood-brain
barrier (BBB). The BBB represents a physical and anatomical
barrier regulating uptake and release of molecules into the
nervous tissue. In thismanner, the brain is protected from the
rest of the body, ensuring homeostasis of the cellular environ-
ment, which is essential for proper neuronal function [1].The
barrier limits entry of undesirable and/or toxicmolecules and
provides a means of removal of toxic substances produced
in the brain. On the other hand, the BBB hinders delivery
to the brain of nutrients and growth factors required for
proper metabolism and nervous function [2]. Over the past
decades it has become clear that the BBB is not as restrictive a
barrier as previously assumed and that the brain is equipped
with an innate immune system including specialized cells
mediating such immune responses [3]. Research within, for
example, the arena of Alzheimer’s disease (AD) has revealed
that neuroinflammation plays an important role in the disease
mechanism and the brain’s efforts to relieve the burden of
amyloid plaques. Other well-documented examples of brain
innate immune system activation involve traumatic brain
injuries [4]. The core cells of the brain’s innate immune
system comprise microglia and astrocytes, which are gaining
increasing attention as regards their involvement in disease
development and progression. Amongst the neurodegener-
ative disorders, AD is considered to be the most common,
affecting millions of people worldwide, with no curative
treatment currently available. Historically, most researchers
have focused their efforts on Amyloid beta (A𝛽) plaques and
neurofibrillary tangles (NFT), which together form themajor
histological hallmarks identified in postmortem AD patient
brains [5]. Surprisingly and unfortunately, all therapeutic
efforts to lower A𝛽 production and plaque load, mani-
festing in reversal of pathological hallmarks in AD mouse
models, have to date shown negligible effects in human
clinical trials. Consequently, the focus of research efforts
that aimed at understanding AD pathology for therapeutic
purposes has shifted and the inflammatory component of
AD has taken a central stage, with immunotherapy being
a potentially promising approach. Although a number of
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antibodies targeting A𝛽 have to some degree been shown
effective in reducing the A𝛽 burden in animal models, the
overall clinical trials have not shown the same results [6].
The lack of positive results could however be due to the
fact that treatment was started too late, and inflammation
remains as a promising target in AD therapeutics. Neuroin-
flammation can be considered as a third hallmark in AD,
highlighting the role of nonneuronal cell types and showing
AD to be amulticellular pathogenesis. Increased activation of
microglia and astrocytes has been identified in AD,manifest-
ing in release of proinflammatory cytokines and neurotoxic
mediators such as tumor necrosis factor-alpha (TNF-𝛼),
interleukin-1𝛽 (IL-1𝛽), IL-6, IL-12, and IL-18, together with
upregulated production of neurotoxic mediators including
proteolytic enzymes, complement factors, nitric oxide (NO),
and reactive oxygen species (ROS) [7].These cell populations
detect and respond to various stimuli such as pathogens and
protein aggregates, as seen in AD, through the activation
of various cell surface receptors. An important group of
such receptors comprises the Toll-like receptors (TLRs). An
increasing body of evidence supports an association between
these receptors and various neurodegenerative disorders.
TLRs not only are expressed by microglia and astrocytes, but
have also been identified on neurons and oligodendrocytes
in the brain [8]. However, the main focus of this review
will be the immune cells of the brain, namely, microglia and
astrocytes. We will provide a general introduction to AD
and neuroinflammation, followed by a review and discussion
of the involvement of TLRs in disease pathology and the
inflammatory response.
2. Alzheimer’s Disease
AD is a neurodegenerative disorder characterized by a pro-
gressive decline in memory and cognitive abilities. AD is
the most common form of dementia, accounting for around
60-80% of all dementia cases, and is the leading cause of
disability in the elderly population, affecting approximately
50 million people worldwide [9]. With age being the most
recognized risk factor for developing AD, the disease is
rapidly becoming an increasing health challenge with a
continuously aging population and no curative treatments
currently available. AD can be characterized as either familial
(fAD) in which mutations in amyloid precursor protein
(APP), presenilin 1 (PSEN1), or presenilin 2 (PSEN2) are
causative of the disease, or sporadic (sAD) with no apparent
heritability. The latter accounts for the majority of all cases
and is associated with genetic risk factors that in combination
with adverse environmental factors confer a certain risk of
developing the disease [10]. fAD and sAD share the same
pathophysiology. Primarily neurons degenerate and lose their
function, eventually resulting in severe brain atrophy. The
AD brain is characterized by two major neuropathological
hallmarks, namely, extracellular deposits of A𝛽 in the form
of senile plaques and intracellular formation of NFTs caused
by tau hyperphosphorylation [5].These hallmarks are mainly
restricted to neuronal pathology. However, emerging evi-
dence implies that immunological processes occur along-
side the degenerating neurons, indicating potential roles
of microglia and astrocytes, hence, neuroinflammation as
a contributor to AD development and progression. Glial
activation has been identified in patients with AD [11] and
elevated levels of cytokines, chemokines, and complement
factors in both the brain and cerebrospinal fluid (CSF) have
been observed in these patients, indicating ongoing neuroin-
flammation. However, the results of studies investigating the
levels of cytokines in theCSF ofADpatients are controversial,
and the time point of sampling and stage of disease have
proved to be an important factor in such studies [12]. Distinct
stages of microglial activation have been suggested to occur
during the course of disease. In early phases of AD, activated
microglia migrate towards A𝛽 deposits and clear them by
phagocytosis, thus providing a protective effect of increased
microglial activation. However, failure to adapt to chronic
A𝛽 deposition results in incorrectly modulated activation
levels and possibly leads to a shift towards a dysfunctional or
neurotoxic microglial phenotype in later AD stages [13, 14].
However, whether neuroinflammation is in fact a cause or
consequence of neurodegeneration remains to be elucidated:
whether the inflammatory response precedes tau and A𝛽
aggregation is the focus of ongoing debate.
2.1. Neuroinflammation in AD. It has become clear that neu-
roinflammation is an important contributor to the complex
pathology of AD. Genome-wide association studies have
revealed a number of genes to be associated with increased
risk of AD, with many of these being expressed by immune
cells, indicating a multicellular pathogenesis and a primary
role of neuroinflammation in AD aetiology [15]. A well-
established example is the gene encoding the triggering recep-
tor expressed on myeloid cells 2 (TREM2). TREM2, which is
highly expressed by microglia, acts as a regulator of phagocy-
tosis and cytokine production; variants within this gene have
been observed in AD patients [16]. Other identified genetic
risk factors include CLU, CR1, and CD33, all associated with
the innate immune system [17], thus further strengthening a
link between inflammation and AD. Aggregation of proteins
has been observed to activate microglia and astrocytes,
and A𝛽 deposition in AD can trigger an innate immune
response. Microglia respond to A𝛽 which initiates migration
to the plaques and phagocytosis of A𝛽, alongside release
of proinflammatory cytokines. Accumulation of activated
microglia has been observed around A𝛽 plaques in both
mouse models and postmortem AD brains [18, 19]. However,
several animal AD models have shown that prolonged acti-
vation decreases microglial efficiency in terms of A𝛽 clear-
ance, while the production of neurotoxic cytokines sustains.
The compromised A𝛽 clearance and persistent release of
proinflammatory mediators in turn damage nearby neurons
further promoting neurodegeneration, accelerating disease
progression [20]. A𝛽 can react with microglial surface recep-
tors and stimulate either the NF-𝜅B-dependent pathway or
activation ofmitogen-activated protein kinase (MAPK) path-
ways, inducing proinflammatory gene expression. A𝛽 has
also been documented to induce NADPH-oxidase-mediated
ROS production in microglia, resulting in increased neuro-
toxicity and neurodegeneration [21]. Although some of the
inflammatory mechanisms involved in AD are understood,
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there is still much debate as to whether neuroinflammation is
causative for AD, as the identification of genetic risk factors
associated with the innate immune system might imply, or
if it is a consequence of other AD pathologies such as A𝛽
accumulation. Precise pathways and other mechanisms of
microglial response in disease thus remain to be elucidated.
As microglia are the resident immune cells of the central
nervous system (CNS), dysfunction in this cell population is
gaining increased attention in terms of the neuroinflamma-
tory response in AD. Normally microglia exist in a “resting”
state, fulfilling such duties as synaptic pruning, to ensure
proper neuronal connectivity. In addition, they play a role
in modulating cognitive functions, such as learning and
memory, and maintain brain homeostasis by secreting neu-
rotrophic factors that promote differentiation and survival of
neurons and by scavenging and removing defective neurons
by inducing neuronal death [22]. As such, microglia perform
“immune surveillance” in the brain: they become activated
in the presence of various stimuli, such as pathogens or
tissue damage, to eliminate the potential threat. Traditionally,
activation of microglia has been categorized as having either
a proinflammatory, toxic state, or an alternative, protective
state. In response to stimuli, these cells have been suggested
to change their phenotype either into the classical “M1”
state, with secretion of proinflammatory cytokines such as
TNF-𝛼, IL-6, and IL-1𝛽 and cytotoxic factors such as NO
and ROS, or to the alternative “M2” state, with secretion
of anti-inflammatory cytokines such as TGF-𝛽 and IL-10
and neurotrophic factors such as BDNF and GDNF. The
latter is thus integral to the downregulation of inflammation
to restore CNS homeostasis [23]. This classification can be
limiting as it only represents two opposite sides of the acti-
vation continuum. Accumulating evidence suggests that the
activation profile ofmicroglia ismultidimensional, indicating
the need of new terminology based on emerging data within
transcriptomics, gene expression, and proteomic analyses
[24]. However, the traditional terms will be further used in
this review, to clearly distinguish between a neurotoxic and
neuroprotectivemicroglial state and their potential beneficial
and detrimental effects in neurodegenerative disorders.Many
of the studies involving microglial activation have been
performed in animal models and have yet to be confirmed
in humans. Such studies give an important insight into the
possible mechanisms of neuroinflammation but need to be
proven in human brain studies to fully understand the human
disease pathophysiology.
In addition to the release of inflammatorymediators, acti-
vated microglia facilitate the crucial process of phagocytosis,
to clear pathogens, debris, or protein aggregates, maintaining
the brain homeostasis.
Accumulation of activatedmicroglia has been detected in
tissue from AD brains, with this activation being particularly
evident around A𝛽 plaques, indicating that microglia can
be activated by A𝛽. These findings go hand-in-hand with
increased proinflammatory factors in these patients, which
might exert detrimental effects on surrounding neurons,
exacerbating disease progression [18]. Conversely, activated
microglia can, as shown in transgenic mouse models, to
some extent, clear the accumulating A𝛽 oligomers through
phagocytosis, providing beneficial effects in AD pathogenesis
[25]. The role of microglia in AD is thus very complex,
with a potential beneficial activation in early disease stages
and detrimental activation in late disease stages. It has
been suggested that dysfunction in these cells promotes the
neurotoxic effects and diminishes the neuroprotective effects
of microglia. Targeting the regulation of microglial activation
might thus serve as a potential avenue to pursue in the
development of AD therapeutics. However, strategies for
targeting microglia and neuroinflammation would have to
be intricately tailored to the stage of the disease, promoting
the beneficial neuroprotective activation in early stages and
suppressing the neurotoxic effects in later stages of the disease
course [26].
Alongside microglia, astrocytes are also currently attract-
ing increased attention for their potential role in AD progres-
sion and likewise converge around A𝛽 plaques in the brains
of AD patients [7]. Astrocytes are the resident cells of the
CNS that play key roles in maintaining brain homeostasis, in
processes such as uptake and recycling of neurotransmitters,
release of gliotransmitters and nutrients, and regulation
of synaptic activity and inflammation [27]. Astrocytes can
release transmitters such as glutamate through calcium-
dependent exocytosis. However, astrocytes can also take
up glutamate via plasma membrane transporters, thereby
serving important functions in both neuronal and glial
communication and in glutamate balance, with potential
impacts on excitotoxicity [28]. Astrocytes also closely interact
with synapses and play a role in synapse formation, function,
and elimination [29]. Astrocytes have also been suggested
to contribute to degeneration in AD and potentially play
an important role in the inflammatory profile observed
in AD pathology [27]. Upon exposure to toxic materials
or injury, astrocytes become activated, transforming both
their morphology and function to become so-called “reac-
tive” astrocytes. Much like microglia, two different states
of reactive astrocytes have been proposed, namely, “A1”
and “A2,” depending on the stimuli. The A1 phenotype
has been observed to be neurotoxic, whereas A2 astrocytes
possess neuroprotective properties.The former predominates
in AD conditions. Astrogliosis, with an increase in reactive
astrocytes, has been observed in AD, and this reactivity
is especially prevalent around A𝛽 plaques. Astrocytes have
thus been suggested to be activated by A𝛽, leading to
overexpression of proinflammatory cytokines such as IL-1𝛽,
TNF-𝛼, and IL-6, in addition to increased formation of ROS
and NO. Resulting elevated oxidative stress levels might then
initiate neuronal degeneration. It has also been proposed
that reactive microglia can induce this A1 state by secreting
cytokines, further promoting formation of reactive astrocytes
and neuroinflammation [27, 30, 31]. Microglia and astrocytes
can thus both play beneficial or detrimental roles in the CNS,
whereby A𝛽 accumulation and inability to resolve plaque
formation can lead to a chronic neuroinflammatory state
as AD progresses, further exacerbating neurodegeneration
(Figure 1).
Initiation of the immune response is triggered by recog-
nition of various pathogens and stimuli, and immune cells
are able to respond to different infections, trauma, brain
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Figure 1: The potential role of neuroinflammation in Alzheimer’s disease. Chronic exposure to inflammatory stimuli such as amyloid beta
(A𝛽) stimulates neurotoxic activation of microglia and astrocytes, triggering the release of proinflammatory cytokines and reactive oxygen
species, promoting degeneration of neurons.
injury, protein aggregation, and neuronal death. Upon dam-
age, immune cells migrate to the injury site and initiate
an immune response. Microglia and astrocytes are able to
recognize such stimuli owing to their expression of specific
receptors, called pattern recognition receptors (PRR). These
receptors can bind and respond to pathogen-associated
molecular patterns (PAMPs) or danger-associated molecular
patterns (DAMPs) such as A𝛽 and in thismannermediate the
inflammatory response. It is through this receptor-complex
that they can interact and react to the A𝛽 accumulation
that occurs in AD [7]. Several types of PRRs are present
on microglia and astrocytes including scavenger receptors,
receptors for advanced glycation end products (RAGE), and
toll-like receptors (TLRs), with the latter being implicated
in AD pathogenesis. TLRs comprise an important group of
PRRs, and various types of these receptors are expressed by
microglia and astrocytes. TLRs are also found on neurons
and oligodendrocytes, and emerging evidence has suggested
involvement of these receptors in AD pathology [7, 32].
3. Toll-Like Receptors
Toll-like receptors are membrane receptors that can detect
and be activated by the presence of pathogens via an
extracellular domain, thereby generating an inflammatory
response. These crucial components of the innate immune
systemwere initially discovered on cells such asmacrophages
and dendritic cells [58, 59]. Subsequently, TLRs have been
identified in a plethora of tissue and cell types including
fibroblasts [60], eye tissue [61], blood cells [62] and, of specific
interest for this review, brain tissue [63].
So far, TLR 1-13 have been identified in mice with the
exception of TLR 10 [64] whereas 10 types of TLRs have
been identified in humans (TLR 1-10) [65–68]. While not
immediately appreciable, this difference is in fact notable and
will be elaborated upon later in this review.
Common to all types of TLRs is their activation by the
presence of a microorganism. Since types of microorgan-
isms far exceed that of TLRs, the TLRs do not recognize
a specific microorganism but instead recognize common
pathogens expressed by different classes of microorganism.
These are referred to as pathogen-associated molecular pat-
terns (PAMPs). In addition to recognition of PAMPs, TLRs
can interact with endogenous molecules such as proteins,
polysaccharides, proteoglycans, nucleic acids, and other cel-
lular components that are released from dead cells or dam-
aged tissues [69]. These components are commonly known
as damage-associated molecule patterns (DAMPs) and can
also be released upon injury or during stress as an indicator
of damage [70].
This section will give a general overview of TLRs with
regard to their activation and signaling pathways. This
overviewwill be based upon activation by pathogens, whereas
more comprehensive details of activation by specific DAMPs
associated with AD will be provided by other sections of this
review.
TLRs can be segregated into two groups known as the
cell surface TLRs and intracellular TLRs. Cell surface TLRs
include TLR 1, 2, 4, 5, 6, and 10 and they can recognize various
membrane components frombacteria such as proteins, lipids,
and lipoproteins. TLR 3, 7, 8, and 9 are intracellular TLRs that
are primarily located in the endosome and lysosome, where
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Table 1: Overview of Toll-like receptors and their binding ligands.
Receptor Ligand (origin)
TLR 2
Lipopeptides (surface of gram positive bacteria)[33], peptidoglycan (surface of gram positive
bacteria)[34], Zymosan (surface ligand on Fungi)[35], Neisserial porins (gram negative
bacteria)[36]
TLR 1/TLR 2 Triacylated lipopeptide (surface of gram positive bacteria)[37]
TLR 2/TLR 6
Diacylated lipopeptide (surface of gram positive bacteria)[38], FSL-1 (synthetic lipopeptide derived
from Mycoplasma salivarium) [39], High mobility group box 1 protein (HMGB1) (endogenous
DNA-binding protein) [40]
TLR 3 Polyinosinic:polycytidylic acid (Poly(I:C)) (synthetic ligand with similar structure to dsRNA)[41],genomic RNA and dsRNA (Viral RNA)[42], Stathmin (endogenous human protein) [43]
TLR 4
Lipopolysaccharide (LPS) (molecule isolated from cell membrane of gram negative
bacteria)[44, 45], Glycosylphosphatidylinositol (GPI) (membrane anchors in Protists)[46], High
mobility group box 1 protein (HMGB1) (endogenous DNA-binding protein) [40]
TLR 4/TLR 6 Amyloid beta (peptides derived from the amyloid precursor gene)[47]
TLR 5 Flagellin (structural part of the flagella found on various bacteria)[48]
TLR 7 ssRNA (virus)[49], Imidazoquinoline derivatives (anti-viral organic compound)[50]
TLR 8 ssRNA (virus)[51]
TLR 9 DNA (virus [52], fungi [53], protists [54] and gram positive [55] and negative bacteria [56]), CpGoligodeoxynucleotides (synthetic single stranded DNA molecules) [57]
TLR 10 Unknown
they can recognize various forms of RNA and DNA from
viruses [71].
TLRs are activated by their respective ligand(s) (Table 1)
binding to a leucine-rich repeat motif located on the outside
of themembrane.The leucine repeats form a horseshoe struc-
ture which helps the ligand to attach to the TLR [72]. After
attachment, the TLR will recruit specific adaptor molecules
via its cytoplasmic Toll/IL-1 receptor (TIR) domain. Adap-
tor molecules that associate with the TIR-domain include
MyD88, MAL, TRAM, and TRIF [73]. Depending on which
adaptor molecule is recruited to the TIR-domain, various
signaling pathwayswill be initiated (Figure 2). As an example,
if TLR4 is stimulated by the presence of lipopolysaccharide
(LPS), it will recruit the MyD88 adaptor molecule to its TIR-
domain. MyD88 then associates with interleukin-1 receptor-
associated kinase 4 (IRAK4) and IRAK1, forming an active
complex that can add a phosphate group to the TNF receptor-
associated factor 6 (TRAF6), allowing TRAF6 to form a
complex that can phosphorylate the IKK-complex. The IKK-
complex is responsible for recruitment of the transcription
factor NF-𝜅B to the nucleus where it increases expression
of cytokines to mediate an inflammatory response [71, 74].
Studies have shown that, in order for TLR 4 to produce an
inflammatory response to LPS, the cofactor CD14 is needed,
as no production is seen in its absence [75]. The release of
cytokines and other inflammatory factors, caused by TLR
stimulation, can initiate a response in surrounding cells,
thereby amplifying immune response.The activation of TLRs
often results in an upregulation of TLR expression, allowing
the cells to detect pathogens more efficiently, producing a
stronger inflammatory response due to this positive feedback
loop [76].
TLRs function as dimers with different types of TLR
receptors forming heterodimers, so increasing ligand
diversity. A high diversity of receptors and pathways allows
for a highly tailored biological response according to the
specific stimulus.
3.1. Toll-Like Receptors in the Human Brain. As elaborated
upon in the previous section, TLRs respond not only to
pathogens but also to the presence of DAMPs. Two main
routes of TLR activation occur in neurodegenerative diseases:
(1) cells undergoing apoptosis and necrosis release their
cellular contents including DAMPs, triggering the immune
response interacting with TLRs [77] and (2) other types of
inflammation factors and protein aggregates directly activate
TLRs [78]. Responses to DAMPs are of specific interest
when studying neuroinflammation in the brain, since these
are triggers from dying neurons and astrocytes and not
caused by bacterial infections. Currently, the stimulation of
TLRs via DAMPs is poorly studied: most investigations of
TLR responses are still performed by presenting pathogen
components to elicit an immune response. This following
sectionwill summarize the various types of TLRs identified in
cells of the human brain, their ligands, and the downstream
activating response.
All ten types of human TLRs have been found to be
expressed in cells of the humanbrain [79] (Figure 3). It should
be noted thatmany studies have investigated the expression of
TLRs inmouse-derived tissue and cells. However, since TLRs
are incompletely conserved betweenmouse and human, only
mRNA and protein encoding TLRs, found in human brain
tissue and cells, will be presented in this section.
3.1.1. Microglia. Microglia cells have been shown to express
mRNA and protein for nine of the 10 TLRs identified in
cells of the human brain (TLR 1-9) [80, 81]. This broad
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Figure 2: TLR signaling pathways. Depending on which TLR is stimulated, adaptor proteins MyD88, TRAM, TRIF, or MAL will associate
with the TIR-site of the receptor. For theMyD88-dependent pathway,MyD88 recruits phosphorylated IRAK1 or 2 and associates with TRAF6.
TRAF6 forms a complex with TAB1, TAB2, TAK1, UEV1A, and UBC13. The complex formation activates TAK1 which then phosphorylates
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of TBK1. TRAF6 results in NF-𝜅B activation and TB1 in activation of the transcription factor IRK3, producing IFN𝛽. TRAF6 activation can
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expression profile is not surprising given that microglia
comprise the brain’s innate immune system and that some
of the inflammatory mediators that microglia produce are
known to be regulated by TLRs. TLR 1 does not appear
to be present in microglia as a homodimer but has been
shown to form a heterodimer with TLR 2, responding to the
spirochete Borrelia burgdorferi, and increases TLR protein
and mRNA expression in astrocytes and glial progenitors
[6]. This finding is informative in dissecting the pathways
underlying neurodegeneration as the Borrelia burgdorferi
infection in some cases affects the nervous system, leading to
dementia [82]. Pathways identified in studies using Borrelia
burgdorferi might therefore overlap with those involved in
DAMP-initiated neurodegeneration.
In other pathological conditions, such as malignant
tumors of the glial tissue of the nervous system (glioma), TLR
1/2 heterodimers, together with TLR 2/6 heterodimers and
TLR 2 in microglia, facilitate infiltration of gliomas into the
brain parenchyma of mice. Interventions into the activation
of these TLRsmight prevent tumor infiltration, increasing the
likelihood of surgical resection [83].
Viral infections such as hepatitis C activate TLR 2 and
TLR 6 in humanmicroglia culture.These have been shown to
respond to the presence of the hepatitis C virus antigen (virus
NS3 protein), releasing the cytokines IL-8, IL-6, TNF-𝛼, and
IL-1𝛽 [84].
Another extensive study has systematically investigated
the innate immune response mediated by TLRs in human
microglia cells [81]. The major findings of this research were
that human microglia express mRNA for TLR 1-9. Moreover,
microglia could be activated through ligation of TLR 2 with
synthetic lipopeptide, TLR 3 with synthetic dsRNA, and TLR
4 with lipopolysaccharide. All of these modes of activation
triggered secretion of proinflammatory cytokines such as IL-
6, IL-10, IL-12, and TNF-𝛼.
All of these studies support the involvement of TLRs
in the innate immune response mediated by microglia,
as they produce proinflammatory cytokines. This immune
response and inflammatory response is intensified by upreg-
ulated mRNA and protein expression of TLR 2 and TLR
3 and downregulated mRNA expression of TLR 4 [81].
For this reaction, microglia interact with astrocytes and
mediate these responses. These findings underscore that glial
activation results in an increased inflammatory response.
Persistent activation of inflammatory responses in the glial
compartment of the brain is characteristic for neurode-
generative diseases and if homeostasis cannot be restored
after the pathogenic components have been removed, these
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Figure 3: Expression of TLRs in human brain cells. Neurons express all ten human TLRs identified to date while microglia express nine of
them. Astrocytes express fewer varieties of TLR and oligodendrocytes only express TLR 2 and TLR 3.
can be considered as potential triggers for disease pathol-
ogy.
3.1.2. Astrocytes. TLR 2 and TLR 3 are the prevalent TLRs in
astrocytes and are both highly expressed on RNA and protein
level [80, 85]. For the other TLRs such as TLR 1, 4, 5, and 9,
astrocytes have lower expression levels of mRNA [81, 86, 87]
and protein [86] while TLR 6, 7, and 8mRNA and protein are
either expressed at very low levels [81, 87] or wholly absent
[86]. TLR 2 mRNA has however also been reported to be
expressed at negligible levels or not at all in astrocytes [81].
The controversy surrounding levels of TLR astrocyte expres-
sion likely reflected differences in detection of TLR between
studies. These might stem from astrocytes not being in the
same activation status or stimulated in differing manners
between studies. This hypothesis is supported by previous
work in mice, showing that activation of TLR 2 heterodimers
TLR 1/2 and TLR 2/6 in microglia is highly dependent upon
the type of stimuli astrocytes have previously been exposed to
[39]. Furthermore some use only fetal samples [86, 87], others
adult [80], and others again both adult and fetal samples [81].
The culture time for the astrocytes varies from 2 passages [81]
to 10 passages [86] which most likely affect the expression
level of TLRs. This is supported by a study showing a 212-
fold difference in TLR 4 gene expression between astrocytes
extracted from human fetal brains and from human adult
brains [88].
In regard to activation and response of TLRs in astrocytes,
TLR 3 and TLR 4 have received the most attention so far.
TLR 3 on human astrocytes has been shown to be activated
by exposure to the synthetic compound poly (I:C) resulting
in increased production of IL-6, IL-8, and TNF-𝛼 [85, 86,
89]. The protein expression of TLR 2, TLR 3, and TLR 4
in astrocytes is enhanced if the astrocyte has been acti-
vated by proinflammatory cytokines such as IFN-𝛾 [80, 83].
This augmented activation by proinflammatory cytokines,
mediated through activation of neighboring astrocytes or
microglia, has been shown to lead to expression of anti-
inflammatory cytokines rendering a neuroprotective effect
[83]. Furthermore TLR 3 activation by poly (I:C) has been
shown to increase ATP release from lysosomes, stimulating
lysosomal clearance of pathogenic substances [90].
TLR 4 can be stimulated by lipopolysaccharides (LPS)
from gram-negative bacteria [81] in the presence of CD14
protein [6]. Astrocytes stimulated with LPS increase their
expression of TNF-𝛼, IL-6, and IL-8 and activate NF-𝜅B
[6, 81], all of which are associated with proinflammatory
signaling. All of these studies underline the importance of
astrocytes within the innate immune response of the brain,
closely collaborating with microglia.
3.1.3. Oligodendrocytes. Work on CNS TLRs has mainly
focused uponmicroglia and astrocytes. However, such recep-
tors have also been identified on oligodendrocytes and
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neurons. Oligodendrocytes are the myelinating cells of the
CNS, providing a supporting role for neurons via axonal
insulation and release of neurotrophic factors. Although
little is known in terms of TLR expression and function in
oligodendrocytes, mRNA expression of TLR 2 and TLR 3
has been identified in these cells, and activation of these
receptors has been suggested to play a role in CNS repair [80].
Besides these findings, an indirect effect of TLR activation via
activatedmicroglia and astrocytes has been proposed to cause
demyelination of oligodendrocytes and their subsequent loss
[91]. Therefore, the direct and indirect effects of TLR activa-
tion can contribute to degeneration of oligodendrocytes in
the brain affecting neurons and their survival.
3.1.4. Neurons. Similar to glial cells, mRNA and protein
expression of TLR have been identified in neurons in both
the peripheral nervous system and CNS. There has been
some controversy in regard to which TLRs are expressed in
human neurons. Whilst some studies have identified only
some of these, another study has detected all 10 TLRs in
human neuronal populations, although the detectablemRNA
expression level varied between different neuronal cell types
[79]. The neuronal expression of such TLRs allows them
to trigger an immune response, indicating the presence of
specific neuronal innate immune machinery. The neuronal
TLR signaling pathways have been suggested to involve
glycogen synthase kinase 3𝛽 (GSK3𝛽), jun-N-terminal kinase
(JNK), and phosphatidylinositol 3-kinase/protein kinase B
(PI3K/AKT). These factors and pathways have been impli-
cated to play a role in the immune response of the brain aswell
as being important for brain development and maintenance
of brain homeostasis [92].
4. Toll-Like Receptors in Alzheimer’s Disease
Various cell types and pathways in the human brain display
a connection with neurodegeneration. The precise mecha-
nisms causing the neuronal death associated with AD are,
however, still unknown. Several studies have implied a role
of TLRs in AD pathology, and in this section the potential
role of such receptors in AD pathogenesis will be discussed.
Our aim is to provide a better understanding of disease
mechanisms and the potential of TLRs as druggable targets
in future therapeutics. Neuroinflammation and the activation
of immune cells are considered a hallmark of AD, and TLRs
have been suggested to play a significant role in this activa-
tion. Stimulation of TLRs and their response is dependent on
the type of stimuli, receptor, and cell population expressing
them and, in this section, the AD-specific TLR response will
be reviewed.
In comparison to healthy brains, brain samples of AD
patients display increased TLR mRNA expression. This
tendency has been observed for all TLR groups, with the
exception of TLR 2 mRNA [93]. The inflammatory response
seen with TLR activation differs depending upon the type
of receptor being stimulated and in what combination they
are activated. For instance, simultaneous stimulation of TLR
4 and TLR 2, TLR 4 and TLR 9 or TLR 2 in combination
with TLR 9 causes a significant increase in inflammation in
mouse models [94]. In microglia from mice it has also been
observed that inflammation is upregulated if both TLR 1 and
TLR 2 are stimulated, compared to a solely TLR 2-mediated
response [95]. Silencing of TLRs has been shown to decrease
the inflammatory response, further indicating an important
role for them in inflammation. This is, however, not seen
for TLR 7 in human AD brains, although an upregulation
of expression in AD mouse models has been reported [96].
These results indicate TLRs to be associated with nonin-
flammatory processes, and TLR 7 has been suggested to be
associated with autophagy in mice [97]. The role of TLRs in
AD pathology is therefore very diverse, depending upon the
exact receptors involved. However, there are clear indications
that these are in fact involved in the neuroinflammation
accompanying neurodegeneration. Further studies must be
conducted in order to confirm the involvement of TLRs in
disease conditions to fully understand the complex signaling
mechanisms at play, as a study made on post-mortem brain
samples from AD-patients and healthy controls showed a
great variation in TLR expression from patient to patient
[80]. In addition, some of these findings are based on mouse
models and should be confirmed in human models. Animal
models do not necessarily recapitulate the precise human
disease pathology, also implicit in the divergence in CNSTLR
expression between rodents and humans.
An article from 2018 has analyzed the expression profiles
from 25 different genetic studies including AD studies [98].
This work has resulted in a public database that includes the
changes in expression profile for a gene of interest. For an
overview, Table 2 has gathered the results from human TLR
1-10 in AD studies in relation to a healthy control.
As evident from the genetic studies, there are differences
between studies of whole tissue and studies of cells, but
also differences between human andmouse studies (Table 2).
In the following section, all results should be considered
carefully, as small differences between studies can cause very
different outcomes.
4.1. A𝛽 and Tau in relation to TLRs. The formation of insolu-
ble A𝛽 plaques and NFTs, the main pathological hallmarks
of AD, is suggested to initiate a cascade of pathological
events that have been previously reviewed to cause neuronal
dysfunction [99]. The involvement of TLRs has been impli-
cated in this cascade: A𝛽 peptides have been suggested to
stimulate TLRs in mice [100] leading to increased mRNA
expression of these receptors [93, 101, 102]. Studies in APP
mouse models have indicated upregulated levels of mRNAs
for TLR 2, TLR 4, TLR 5, TLR 7, and TLR 9, compared to TLR
expression in plaque-free tissue. In contrast, TLR 3 mRNA
expression was shown not to be significantly altered in AD
mouse models, indicating that both activation and response
in AD conditions are specific for different types of TLRs
[103]. These findings also emphasize the potential differences
between TLRs in rodents compared to humans. In contrast to
mice, TLR3mRNAandprotein are upregulated in humanAD
brains and TLR 2 expression is not significantly increased, as
previouslymentioned. Differences betweenmodel organisms
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Table 2: Overview of TLR expression in various AD or LPS studies compared to a healthy control. Data from database
(http://research-pub.gene.com/BrainMyeloidLandscape).
Receptor Mouse Mouse Human LPS treatment
cell studies Whole tissue Whole tissue 1Microglia 2Cortical
TLR 1 Up Up Not significant 1Up 2Up
TLR 2 Up Up Up 1Up 2Up
TLR 3 Down Up Up 1Down 2Up
TLR 4 Down Up Up 1Down 2Down
TLR 5 Down Up Up 1Down 2Down
TLR 6 Down Up Up 1Up 2Up
TLR 7 Not significant Up Up 1Down 2Up
TLR 8 Not significant Not significant Up 1Up 2Up
TLR 9 Down Up Up 1Up 2Same
TLR 10 Not tested Not tested Up Not tested
should thus be considered in future research, to fully under-
stand the human disease aspect. The increase in TLR expres-
sion resulting from A𝛽 stimulation correlates with increased
inflammatory response. For instance, addition of A𝛽 to
mouse hippocampal neurons upregulates TLR 4 protein,
which then shows a stronger response to lipopolysaccharide
(LPS) treatment, and increased neuronal death [104].
Based on various mouse models, TLRs have also been
suggested to play a role in A𝛽 clearance by microglia, and
such phagocytosis is likely dependent upon TLR 2, TLR 4,
and TLR 9 [105–107]. TLR 2 mediates interaction between
microglia and A𝛽 and has been suggested to serve as an
important trigger for neuroinflammation in AD. Deficiency
of TLR 2 in mice has been suggested to reduce inflammation
and increase clearance of A𝛽, favoring the microglial M2
phenotype and neuroprotection, improving neuronal func-
tion. Such deficiency could thus be beneficial by inhibiting
A𝛽-induced neuroinflammation [95]. In addition, TLR 2
deficiency has been observed to relieve tauopathies in mice,
indicating further beneficial effects. These studies imply that
TLR 2 activation contributes to inflammation and neurode-
generation, and inhibiting TLR 2 function might potentially
slow disease progression. However, there is some controversy
regarding TLR 2 and its involvement in AD. Although
deficiency of the receptor has been implicated as beneficial,
conflicting results have demonstrated TLR 2-mediated A𝛽
uptake, and activation of TLR 2 with, for instance, pepti-
doglycan (PGN) has been reported to promote microglial
phagocytosis of A𝛽 in mice. It has been suggested that this
promotes M1 microglial activation and a proinflammatory
state [108]. The hypothesis that TLR 2 is involved in the
proinflammatorymicroglia response has also been supported
by a study showing that the coreceptor CD14 must act
together with TLR 2 and TLR 4 in order for fibrillary A𝛽 to
bind and trigger a microglial response in mice [109]. Despite
the controversy, these findings clearly indicate a role for TLR
2 in the inflammatory profile associated with AD.
TLR 4 is the other major receptor involved in A𝛽
activation of microglia. Upregulation of TLR 4 mRNA has
been observed in AD transgenic mice, and TLR 4 expression
is increased in brain tissue surrounding A𝛽 plaques [101].
Deficiency of TLR 4 in microglia from such mice has also
been demonstrated to increase A𝛽 deposits [110], indicating
that TLR 4 is also required for microglial activation [106].
Besides TLR 2 and TLR 4, the role of TLR 9 in AD
pathology and inflammation has been probed by a number
of studies. Stimulation of TLR 9 has been demonstrated to
increase microglial recognition of A𝛽42 [107] and A𝛽 uptake
[110] in mice. TLR 9 can bind DNA containing unmethylated
cytosine-guanosine (CpG) sequences, commonly found in
bacteria and viruses, and such stimulation has been shown
to reduce A𝛽 in the cortical regions of AD mouse models
[111] and restore cognitive function in AD mice as a result
of the TLR9 stimulation [112]. This has also been observed
in cocultures of neurons and microglia in which stimula-
tion of TLR 9 led to reduced toxicity of oligomeric A𝛽,
with increased microglial clearance without production of
neurotoxic factors [113]. The use of TLR9 agonists in mouse
studies has not raised any safety concerns [114], but tests
need to be made in humans, as it is likely that the increased
inflammatory response, caused by stimulation of TLR9, can
have a negative effect even though a study has shown that
activation of TLR9 in mice does not worsen A𝛽-induced
microglial activation [115]. Taken together, these findings
render TLR 9 an attractive candidate to investigate further
regarding the development of future AD therapies.
Although most studies involving TLRs in AD pathology
have focused upon TLR 2, TLR 4, and TLR 9, other TLRs
might also potentially play a role in AD development.
Interestingly, some genetic variants of TLR 5 in mice have
been suggested to be preventive for AD [116]. Expression of
the ectodomain of TLR 5, mediated by Adenoviral vectors,
has been shown to result in decreased A𝛽 accumulation.This
ectodomain can form a complex with A𝛽, thus preventing
aggregation and toxicity, making it more susceptible for
removal [116]. Studies involving both TLR 9 and TLR 5 thus
point towards promising therapeutic potential of TLRs inAD.
Compared to the many studies on A𝛽 and its interaction
with TLRs, limited data is available regarding tau tangles and
TLR response. TLR 3 protein expression has been shown
to increase correspondingly with the level of tau tangles
in human cell culture and brain samples [93]. However,
10 BioMed Research International
stimulation of TLR 3 did not seem to impact microglial
activity in these cases. Conversely, mild stimulation of TLR
4 with LPS in transgenic mice overexpressing human mutant
tau in neurons resulted in enhanced autophagy and reduction
in phosphorylated tau, indicating that neuroinflammation
promotes autophagy. Chronic mild stimulation of TLR 4
might thus possibly attenuate AD-related tauopathy, by
providing beneficial neuroinflammation, which might be
exploited in AD treatment [117].These studies hence indicate
that TLR signaling might also be linked with tau pathology.
4.2. Activation of Microglia. As previously described, A𝛽
plays a major role in microglial activation in AD. Studies
have shown that A𝛽42 protofibrils, an intermediate pre-
ceding amyloid fibril formation, can trigger the MyD88-
dependent pathway in microglia. Such activation favors the
M1 microglial phenotype and causes secretion of proinflam-
matory mediators [118]. Microglial activation can be medi-
ated by TLRs, and expression of TLR 1-9 mRNA is seen in
microglial cells. Stimulation of TLR 2, TLR 4, andTLR 9 leads
to activation of this cell population, characterized by release
of cytokines such as TNF-𝛼, IL-1𝛽, and IL-12, in addition to
nitric oxide.This has been confirmed by in vitro studies using
agonists for TLR stimulation [119–121], and simultaneous
stimulation of microglia with even low concentrations of
TLR ligands has been shown to result in an additive effect,
indicating that low amounts of pathogens can manifest in
TLR activation, if multiple TLRs are targeted [121]. The exact
mechanism(s) through which TLR activation can influence
AD pathology and if this is the case is not fully understood,
as well as the mechanisms causing AD. However, a con-
stituent of the signaling pathways has been identified and is
likely mediated by the MyD88/TRAF6//MAPK/IKKs/NF-𝜅B
pathway or the MyD88/PI3K/NF-𝜅B pathway, both of which
promote M1 activation [122].
Depletion of both TLR 2 and TLR 4 has been observed
to decrease microglial activation. However, while deficiency
for TLR 2 has been linked with reduced A𝛽 plaque burden
[100], TLR 4 deficiency has been observed to increase A𝛽
deposition [123]. In contrast, TLR 4 inhibition has been
observed to result in reduced secretion of proinflammatory
cytokines [101].The fact that deficiency of these receptors can
reduce the inflammatory response in AD suggests an impor-
tant role of these TLRs in microglial activation. However,
activation is not solely dependent upon TLRs, and activation
can occur in TLR 2- and TLR 4-deficient conditions via other
factors such as ROS-mediated activation, but under such
circumstances, very high levels of LPS are required to induce
an inflammatory response [124].
Suppression of TLR 4 appears to improve cognitive
deficits and decreases inflammatory injury in mice with AD
mutations [125]. By targeting TLR 4 signaling pathways,
inflammation can thus potentially be decreased. Chronic
activation of TLR 2 and TLR 4 has been suggested to con-
tribute to neuroinflammation. However, further studies are
required as conflicting results remain in terms of the effects of
activation and silencing of the same receptors. Conversely, all
studies regarding TLR 9 activation of murine microglia have
shown consistent results, leading to an ultimate decrease in
A𝛽 [107, 111, 113] as described in the previous section. A𝛽 has
also been observed to induce dimerization of TLR 4 and TLR
6 in mice, and inhibiting this process led to decreased release
of proinflammatory cytokines from microglia, providing a
neuroprotective effect [126].
Activation of microglia can result in different outcomes,
either leading to the proinflammatory M1 state, or the
anti-inflammatory M2 state, promoting neurotoxicity and
neuroprotection, respectively.The balance between these two
phenotypes is essential in terms of neuroinflammation and
maintaining brain homeostasis [127]. In terms of neurode-
generation, this balance is shifted towards the M1 microglial
phenotype, promoting the release of proinflammatory medi-
ators and neuroinflammation [127]. Whether the observed
inflammatory profile in AD is a direct cause of the disease
or if it is in fact a secondary reaction to other AD pathologies
is, however, still hotly contested.
Some studies have suggested that neuroinflammation in
AD occurs due to the fact that microglia become senescent,
and thus less responsive to stimuli [128]. Concordantly,
repeated treatment of murine microglia with LPS has been
demonstrated to drive them towards a senescent state [129].
Mouse studies showing no difference in the prevalence of
active microglia between postmortem AD and control brains
have supported this theory. The fact that LPS stimulation,
which acts on TLR 4, can induce this microglial state invoked
the hypothesis that chronic exposure to stimuli such as A𝛽
leads to less responsive microglia, decreased A𝛽 clearance,
and thus accelerated AD progression [130]. Studies in mice
have also indicated that age plays a role in microglial activa-
tion.Microglia fromoldermice have been observed to secrete
higher amounts of proinflammatory cytokines compared to
those from younger mice [131], and these microglia are less
responsive to other stimuli. Chronic activation of microglia
can thus lead to a state in which these cells are no longer able
to respond to additional stimuli [132].
A recent study has shown that stimulation of microglia
can lead to epigenetic reprogramming, traceable for up to
6 months [133]. In this study, two types of immunological
imprinting were distinguished from one another, namely,
training and tolerance, which can respectively enhance or
suppress the inflammation [133].This finding emphasizes that
the type of stimulus can influence the inflammatory signaling
pathway and produce distinct outcomes despite targeting the
same TLRs.
4.3. Reactive Astrocytes. Besides microglia, reactive astro-
cytes play a role in neuroinflammation and neuronal death
in AD. Activation of TLRs in human and rat astrocytes leads
to secretion of TNF𝛼, IL-6, IL-8, IL-10, IL-1𝛽, and inducible
nitric oxide synthase [86, 87, 134, 135]. TLR stimulation in
these cells likely involves theNF-𝜅B signaling pathway, which
has been shown to induce astrogliosis and neuroinflamma-
tion in mice [136]. Increased TLR 2 expression in astrocytes
has also been demonstrated to increase the secretion of
proinflammatory cytokines, further indicating that TLRs
are implicated in the inflammatory response. In contrast,
astrocytes from TLR 2-deficient mice have been found to
show reduced production of inflammatory mediators [137].
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Furthermore, activation of TLR 3 in rats has been seen to
increase the proinflammatory phenotype of astrocytes, con-
tributing to neurotoxicity [138], whilst TLR 9 stimulation in
mice has resulted in reactive astrogliosis, further emphasizing
the role of TLRs in neurodegeneration [139].
Astrocytes can thus be activated by TLR recognition of
different stimuli. However, these cells can also respond to
cytokines of the adaptive immune system such as IFN-𝛾 and
TNF-𝛼. Innate signals such as LPS and TLR ligands have
been shown to elicit a stronger upregulation of TLRs and
increase in cytokine release compared to cytokine-stimulated
astrocytes.These findings clearly indicate that different stages
of neurodegeneration can generate altered responses in
astrocytes and are important for understanding the role of
astrocytes in inflammation and neurodegeneration [140].
4.4. Implications of TLR Activation in Neurons. Activation
of TLRs can produce either direct or indirect effects on
the neuronal population of the CNS. The direct effect of
TLRs can be seen from studies of knock-out mice. In TLR
2-deficient mice, differentiation of neural progenitor cells
into neurons is favored over astrocytes, resulting in reduced
plasticity while TLR 4-/- mice show increased proliferation
and differentiation of neural progenitor cells [141]. Together,
these findings show that TLRs are involved in neurogenesis
and therefore most likely are involved in neurodegenerative
mechanisms of AD. In accordance with this notion, mouse
models have shown that neurons can respond directly to the
presence of A𝛽 through TLR 4, and such stimulation can
lead to apoptosis [142]. By downregulating TLR 4, neurons
showed greater survival and less sensitivity to A𝛽. The same
study looked at the levels of TLR 4 in brains fromADpatients
and healthy controls and found lower TLR 4 levels in AD
patients, indicating that neurons expressingTLR4died. TLRs
thereby directly impact neuronal health in AD. Because TLR
4 is also expressed in healthy neurons, apoptosis cannot be
explained by the presence of TLR 4 alone but it is clearly
involved in the process.
Furthermore, neurons can be affected by the neuroin-
flammation initiated by microglial activation as this process
initiates a cascade of proinflammatory events. Stimulation
of TLR 2 and TLR 4 in mice by A𝛽 activates microglia and
causes secretion of proinflammatory cytokines [105] which
can have detrimental effects on the surrounding neurons,
hence promoting neurodegeneration.
A connection between neurons, neurodegeneration, and
TLRs has also been found in human brain samples of patients
with Parkinson’s disease [143], where expression of the TLR 2
protein was found to be increased in patients.The same study
showed that activation of TLR 2 in human cells increased
the production of 𝛼-synuclein, a well-known hallmark of
Parkinson’s disease, but also a protein that has been associated
with AD [144].
The activation of TLRs can thus affect the neuronal
population, directly or through microglia-mediated inflam-
mation, both of which should be studied further to increase
our understanding of how these pathways work together to
exacerbate neurodegeneration.
4.5. Aging/Stress. Thenumber of people affected by dementia
is expected to reach 152 million by 2050, due predominantly
to increased longevity [145].
Many studies have shown that chronic stress increases
the risk of developing AD as the body cannot normalize
its homeostasis which progressively affects the physiological
balance [146], leading to neurodegeneration [147]. Stress in
fAD mice has been shown to mainly affect the hippocampal
region of female mice, indicating stress pathology to be
region- and sex-specific [148].
Chronic stress can lead to induction of proinflammatory
mechanisms, causing oxidative stress due to generation of
oxidative species [146]. As humans are exposed to stress
throughout their lives, it is not a direct cause of AD, but
stress might increase the level of damage in brains susceptible
to neurodegeneration. It is therefore of interest to study the
effect of stress on aging cells, as these are more susceptible to
damage [149].This effect has been studied in neonatal mouse
microglia cells cultured for 16 days in vitro and investigated on
days 2, 10, and 16 [127]. On day 2, microglia showed adaptable
morphology and expressed markers of reactive phenotype
whereas microglia on day 16 showed branched morphology,
increased NF-𝜅B activation, and glutamate release. Thus,
old microglia cells (day 16) behave in a similar fashion as
irresponsive/senescent microglia. Microglia from old mice
secrete greater amounts of IL-6 and TNF-𝛼 compared to
those from young mice and are less responsive to stimulation
[131]. These findings indicate a higher detrimental effect of
stress in aging microglia, supporting the hypothesis that
brains of elderly people are more vulnerable to neuroinflam-
mation.
In relation to TLRs, expression of TLR 2 and TLR 4 in
microglia has been shown to decrease with age [104] together
with the capacity to migrate and phagocytose. In correlation
with this, the general level of functional TLR 1, 6, and 10
in human DNA from healthy old people has been shown
to decrease [150], indicating that a downregulation of these
TLRs in general might provide a beneficial effect in aging.
Other genetic studies have highlighted the potential
influence of TLRs in AD, in which TLR 2 emerges as a
potential risk factor in late onset AD [151, 152]. In a genetic
study of a Chinese population, TLR 2 was not identified
as a significant genetic risk factor for AD [153]. This might
be explained due to differences in populations and testing
protocols. All these findings together with the observation
that mice deficient for TLRs show less cellular damage after
exposure to stress [154] confirm that a relation between age,
stress, TLRs, and inflammation exists but that further studies
are needed to elucidate their relationships to one another.
4.6. Components Known to Decrease Inflammation via TLR
Pathways. Ever-increasing numbers of studies have inves-
tigated potential therapeutics targeting the TLR signaling
pathway to decrease neuroinflammation.
Treatmentwith Picroliv inmouse brains has been demon-
strated to reduce the effect of the TLR 4/NF𝜅B pathway,
resulting in decreased expression of TLR 4, BDNF, IL-1𝛽
protein, and A𝛽 levels [155].
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Stachydrine also reduces the levels of IL-1𝛽, TNF𝛼, and
INF-𝛾 via the TLR 4/NF𝜅B pathway upon brain injury
[156]. Treatment with Betainine and various polyphenols also
exhibits anti-inflammatory effects by decreasing production
of proinflammatory cytokines and increasing the release
of anti-inflammatory cytokines [157, 158]. This shows that
Betainine treatment promotes conversion of microglia from
theM1 stage to theM2 stage, which is achieved by suppression
of the TLR 4/NF𝜅B pathway.
Together, these studies show that targeting the TLR 4/NF-
𝜅B-pathway decreases inflammation, rendering this pathway
of therapeutic potential. As members of the NF𝜅B family
in general regulate inflammation by mediating synthesis
of proinflammatory proteins, they are potential druggable
targets for decreasing inflammation [159].
As another study has shown that combinatorial TLR acti-
vation results in increased inflammatory response and that
the response depends on which specific TLRs are activated
[94], other pathways and TLRs should be studied further to
dissect potential involvement in AD pathogenesis.
5. Discussion
5.1. Study of TLR inHuman versusMouse. Thevarious studies
presented above were conducted in different models: while
some pertain to human cells/tissues, the vast majority was
performed in rodents. All of the TLRs identified in humans
are also expressed inmice. However, themouse exhibits three
additional TLR members not found in humans [71].
While numbers of TLR members expressed between
mouse and human brain cells diverge, so too do the expres-
sion levels of each member. Mouse astrocytes express TLR 1-
6 and very low levels of TLR 7-9 [140, 160] whereas human
astrocytes only express TLR 1-6 and 9. In neurons, humans
express all 10 TLRs, whereas studies in mice have shown
their cortical neurons to only express TLR 2, 3, and 4 [161].
Other significant differences between the innate immune
systems of mouse and human include the finding that RNA
is sensed by TLR 3, 7, and 8 in humans but by TLR 13 in
mice, a receptor that does not exist in human cells [71, 162].
Furthermore, human TLR 9 recognizes the GTCGTT DNA
sequence from bacteria whereas mouse TLR 9 recognizes
the GACGTT sequence [163]. These studies clearly reveal
substantial differences in numbers, expression levels, and cell
type-specific expression patterns between mouse and human
which need to be taken into consideration if mouse models
are employed to study the role of TLRs in neurodegenerative
diseases and to identify potential drugable targets.
Despite these differences, mice remain the most common
model to investigate AD and other human diseases. Mice
are important in vivo models since they can easily be bred,
and knock-out, transgenic, and knock-in lines have been
generated for diverse studies. Furthermore, humans andmice
sharemany genetic and physiological similarities, which have
helped elucidate many pathways in mice, which have then
subsequently been confirmed in humans. [164]. However,
major disadvantages of mouse models are that mice do not
naturally develop AD and their longevity is too brief to
develop the hallmarks of sporadic AD [165]. Therefore, in
order to investigate AD pathology in mice, either transgenic
mouse models with several strong pathogenic mutations are
employed [166], or some of the pathogenic hallmarks such as
A𝛽 or tau are directly injected into themouse brain [167–169].
Taken together, owing to the challenges of TLR diver-
gence between mouse and man and the difficulty in recapit-
ulating AD pathology in mouse models, alternative experi-
mental models should be sought.
5.2. Use of iPSC Models and Future Studies. One potential
model for studying the functional roles of TLR in AD
is the use of induced pluripotent stem cells (iPSC). iPSC
possess the advantage that they can easily be generated from
human fibroblasts [170] collected from skin samples, blood,
or even urinary epithelial cells. This allows for investigation
in cell lines generated from different individuals and thereby
cell lines with different genetic backgrounds. Comparative
studies can be made as samples can be taken from both AD
patients and healthy controls.
Furthermore, gene-editing technologies such as TALENS
and CRISPR-Cas9 allow for insertion of pathogenic muta-
tions into healthy control iPSCor for correction of pathogenic
mutations in patient iPSC, allowing for the establishment
of isogenic control lines with the same genetic background.
Many protocols have been developed to differentiate iPSC
into various cell types, such as astrocytes [171, 172], neurons
[173], and microglia [174]. It will be very interesting to
investigate the expression patterns of TLRs in iPSC-derived
neurons, astrocytes, microglia, and oligodendrocytes and to
compare these with human brain samples in order to validate
these in vitromodels.
If the same expression patterns in the diverse iPSC-
derived models can be validated, these cells would represent
valuable tools for the identification of compounds to develop
drugs targeting TLR activity and innate immune responses
as well as for understanding the human-specific function of
TLRs.Another possibility in order to study theTLR responses
of human-derived cells in a complex in vivo system would be
the transplantation of such cells into humanized AD mouse
models, even though the investigation of such transplants
is hindered by the fact that these mice must remain in an
immunocompromised state.
6. Conclusion
In this reviewwe have presented the different TLR expression
patterns in the main cell types of human brains, their
responses to pathogenic triggers, and secretion of proin-
flammatory cytokines. These different cell types are closely
dependent on the innate immune responses of each other and
facilitate either increased immune responses or restoration
of the homeostatic state depending on the environmental
situation in the brain. Moreover, we have described and
discussed that microglia and astrocytes specifically respond
to A𝛽 and tau, underlining the importance of TLR-mediated
innate immune response in AD. Since the responses to
A𝛽 and tau are late pathological events, the responses to
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DAMPs released by degenerating neurons are even more
intriguing in order to understand early AD pathology linked
to inappropriate innate immune responses and potential drug
development targeting the mild cognitive impairment state
of the disease. Moreover, we have discussed the divergence
in numbers and expression patterns of human- and mouse-
specific TLRs in the brain, emphasizing the importance of
human in vitro models, such as iPSC, to investigate the
human-specific innate immune response in the various brain
cell types facilitated by TLRs.
In conclusion, more studies are needed to elucidate the
impact of TLRs in the human-specific context and in relation
to AD.
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